The Journal of clinical investigation

Amphiphysin (BIN1) limits dynamin 2 to support normal muscle development

Updated

Abstract

Bin1-/- Dnm2+/- mice survived at least 18 months with normal muscle force and organization despite the absence of BIN1.

  • BIN1 is identified as a negative regulator of DNM2, influencing muscle development.
  • While BIN1 and DNM2 interact during muscle maturation, BIN1 does not affect the adult muscle isoform of DNM2.
  • The study suggests that DNM2 modulation could offer therapeutic possibilities for patients with centronuclear myopathies and BIN1 mutations.
  • Findings indicate that the interplay between BIN1 and DNM2 may also have implications for conditions such as cancer, arrhythmia, and Alzheimer disease.

Simplified

Full Text

Full text is available at the source.

Funding

Competing interests

Conflict of interest: H. Tasfaout, J. Laporte, and B.S. Cowling are inventors on a patent (number Ep13306440.2 - 1412 [EP20130306440], filed 10/28/2013, second file international extension [PCT] PCT/EP2014/072466, 10/20/2014) for targeting DNM2 for the treatment of centronuclear myopathies, and cofounders of Dynacure. J. Laporte and B.S. Cowling are scientific advisors for Dynacure.
PubMed

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free